Emerald Investment Advisers LLC Takes $3.49 Million Position in LeMaitre Vascular, Inc. $LMAT

Emerald Investment Advisers LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 36,366 shares of the medical instruments supplier's stock, valued at approximately $3,490,000. Emerald Investment Advisers LLC owned about 0.16% of LeMaitre Vascular at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Illinois Municipal Retirement Fund boosted its stake in LeMaitre Vascular by 1.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier's stock worth $906,000 after purchasing an additional 123 shares during the period. NewEdge Advisors LLC grew its position in LeMaitre Vascular by 4.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier's stock worth $256,000 after purchasing an additional 139 shares during the last quarter. Federated Hermes Inc. increased its stake in LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier's stock valued at $3,294,000 after purchasing an additional 155 shares during the period. Pictet Asset Management Holding SA increased its stake in LeMaitre Vascular by 5.5% in the first quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier's stock valued at $356,000 after purchasing an additional 169 shares during the period. Finally, Sound Income Strategies LLC raised its holdings in shares of LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 183 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 0.6%

Shares of LeMaitre Vascular stock opened at $81.86 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of 28.72, a PEG ratio of 2.36 and a beta of 0.53. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. LeMaitre Vascular, Inc. has a one year low of $78.65 and a one year high of $118.01. The firm has a fifty day moving average of $94.38 and a two-hundred day moving average of $99.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The firm had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. During the same quarter last year, the business posted $0.60 EPS. The firm's revenue was up 9.6% on a year-over-year basis. On average, analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular's payout ratio is presently 35.09%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent research reports. Citigroup reiterated a "market outperform" rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Zacks Research downgraded LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Wells Fargo & Company decreased their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 5th. Finally, Wall Street Zen downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source